Immune cell therapy for hard-to-treat IgG4-related disease
Part of Immune system & allergy clinical trials.
This study tests a new type of cell therapy (CAR-NK) that uses your own immune cells to target and attack the cells causing your IgG4-related disease. It may help people whose disease has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of IgG4-related disease (a condition causing swelling and scarring in tissues).
- Your disease must be active or have returned despite standard treatments (like steroids or other immune drugs) for at least 3 months.
- Your heart, lungs, and labs (like blood counts and liver/kidney function) must be in acceptable ranges.
- You cannot have other serious medical conditions like cancer, active infections, or severe allergies.
- Women who can have children must use reliable birth control during the study and for 6 months after the final treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This trial tests a new treatment called BCT301 for people with IgG4-related disease (an autoimmune condition causing swelling in organs like the pancreas or kidneys) that has not improved with standard treatments. The therapy targets certain immune cells to help reduce disease activity.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.